Literature DB >> 32524013

ADRENAL INSUFFICIENCY SECONDARY TO BILATERAL ADRENAL HEMORRHAGE ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME.

Rashika Bansal, Priti V Nath, Thanh D Hoang, Mohamed K M Shakir.   

Abstract

OBJECTIVE: Antiphospholipid syndrome (APS) can involve multiple organ systems but endocrine manifestations are rare. In most cases adrenal insufficiency (AI) is the first endocrine manifestation of APS. The prompt diagnosis of AI is critical as this disorder is a life-threatening disease that may lead to fatal outcomes if left untreated. We present a case of AI associated with APS the patient was diagnosed promptly and managed successfully.
METHODS: The diagnosis of APS was based on a combination of clinical features (deep venous thrombosis and pulmonary embolism) and laboratory findings (lupus anticoagulant, anticardiolipin antibody, anti-beta-2 glycoprotein-I antibody), without alternative diagnosis to explain the clinical findings. AI was diagnosed by low morning serum cortisol with elevated adrenocorticotropic hormone (ACTH) level as well as an ACTH stimulation test.
RESULTS: A 50-year-old male presented with deep venous thrombosis of the left extremity diagnosed by compressive ultrasound, and was subsequently diagnosed with a pulmonary embolism by computed tomography angiography and treated with heparin. Two days later, he developed hypotension and bilateral flank pain, and an abdominal computed tomography scan revealed bilateral adrenal hemorrhage. Laboratory results showed a serum cortisol of 3.3 mcg/dL (stress normal, 25 to 35 mcg/dL) and ACTH of 319 pg/mL (stress normal, 128 to 218 pg/mL), consistent with primary AI. Symptoms improved quickly with hydrocortisone therapy. The patient still required glucocorticoid therapy for at least 4 years thereafter.
CONCLUSION: In all cases of adrenal hemorrhage and infarction with unknown etiology, screening with lupus anticoagulant and anticardiolipin antibodies is imperative. Recognition of this high-mortality condition allows for appropriate screening and confirmatory tests leading to a prompt diagnosis and timely management.
Copyright © 2020 AACE.

Entities:  

Year:  2019        PMID: 32524013      PMCID: PMC7282157          DOI: 10.4158/ACCR-2019-0376

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  17 in total

1.  The blood supply of the kidney, suprarenal gland, and associated structures.

Authors:  B J ANSON; E W CAULDWELL
Journal:  Surg Gynecol Obstet       Date:  1947-03

2.  Adrenal insufficiency in systematic lupus erythematosus (SLE) and antiphospholipid syndrome (APS): A systematic review.

Authors:  Keum Hwa Lee; HyunJeong Lee; Cheol-Hun Lee; Jin Yeong Kim; Jong Min Kim; Se Seung Kim; Seungmin Jeong; In Sung Hwang; Namsoo Kim; Na Eun Kim; Soogeun Shin; Dongkwan Shin; Joo Sang Song; Dong Hyun Shin; Jung Dong Kim; Jeehoon Kim; Yong Seok Lee; Hansung Kang; Dong Ha Kim; So Hyun Moon; Won Suk Rho; Joo Yeon Lee; Andreas Kronbichler; Jae Il Shin
Journal:  Autoimmun Rev       Date:  2018-11-05       Impact factor: 9.754

Review 3.  Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature.

Authors:  Fabio Presotto; Francesca Fornasini; Corrado Betterle; Giovanni Federspil; Marco Rossato
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

Review 4.  [Acute adrenal insufficiency caused by bilateral adrenal hemorrhage as first manifestation of antiphospholipid syndrome. Report of a case and review].

Authors:  G Barreiro García; M V Egurbide Arberas; A Alvarez Blanco; J Ugalde Espiñeira; C Aguirre Errasti
Journal:  An Med Interna       Date:  2002-01

5.  Adrenal hemorrhage: a 25-year experience at the Mayo Clinic.

Authors:  A Vella; T B Nippoldt; J C Morris
Journal:  Mayo Clin Proc       Date:  2001-02       Impact factor: 7.616

6.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

Review 7.  Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.

Authors:  Gerard Espinosa; Eugénia Santos; Ricard Cervera; Jean-Charles Piette; Gloria de la Red; Víctor Gil; Josep Font; Robert Couch; Miguel Ingelmo; Ronald A Asherson
Journal:  Medicine (Baltimore)       Date:  2003-03       Impact factor: 1.889

8.  Adrenal insufficiency attributable to adrenal hemorrhage: long-term follow-up with reference to glucocorticoid and mineralocorticoid function and replacement.

Authors:  Maryam Jahangir-Hekmat; Harris C Taylor; Howard Levin; Margaret Wilbur; Luis A Llerena
Journal:  Endocr Pract       Date:  2004 Jan-Feb       Impact factor: 3.443

9.  Antiphospholipid syndrome and endocrine damage: why bilateral adrenal thrombosis?

Authors:  Kaspar Berneis; Carlos Buitrago-Téllez; Beat Müller; Ulrich Keller; Dimitrios A Tsakiris
Journal:  Eur J Haematol       Date:  2003-10       Impact factor: 2.997

10.  Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients.

Authors:  Isolde Ramon; Alexis Mathian; Anne Bachelot; Baptiste Hervier; Julien Haroche; Du Boutin-Le Thi Huong; Nathalie Costedoat-Chalumeau; Bertrand Wechsler; Rafik Karmali; Brigitte Velkeniers; Philippe Touraine; Christiane Coussieu; Abdelhai Bennani; Raphaele Renard-Penna; Philippe A Grenier; Denis Wahl; Jean-Charles Piette; Zahir Amoura
Journal:  J Clin Endocrinol Metab       Date:  2013-06-19       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.